Literature DB >> 31836919

Chrysophanol suppresses growth and metastasis of T cell acute lymphoblastic leukemia via miR-9/PD-L1 axis.

Junjie Yin1,2, Qingsong Yin3, Bo Liang2, Ruihua Mi1, Hao Ai1, Lin Chen1, Xudong Wei1.   

Abstract

T cell acute lymphoblastic leukemia (T-ALL) was a malignant lymphoma. Therefore, the development of novel therapeutic agents against T-ALL is imperative. Previous studies have shown that chrysophanol (CHL), an anthraquinone compound isolated from the Rheum palmatum L., exerts anti-proliferative and anti-metastatic effects in multiple malignant tumors. However, the effect of CHL on the progression of TALL is poorly understood. The aim of this study was to explore the role of CHL in the biological behavior of T-ALL cells and determine its underlying mechanism. Both T-ALL cell lines (Jurkat and TALL-104) were treated with CHL. The proliferation, apoptosis, migration, and invasion of T-ALL cells were determined by CCK-8, flow cytometry, wound healing, and Transwell assay, respectively. Western blot and RT-qPCR were applied to examine gene expression. The dual-luciferase reporter gene assay was employed to examine the regulation mechanism of miR-9 and PD-L1. A T-ALL xenograft model also was used to examine the effect of CHL on the tumor growth and metastasis in vivo. CHL treatment significantly inhibited the proliferation, migration, and invasion ability of both Jurkat and TALL-104 cells and induced cell apoptosis and the expression of miR-9. Moreover, miR-9 was proved to target PD-L1 by binding to its 3'-untranslated region (UTR). Mechanically, pretreated with PD-L1 inhibitor could augment the anti-proliferation and anti-metastatic effect of CHL, while miR-9-silenced alleviated this effect. Consistent with in vitro studies, CHL significantly suppressed the growth and metastasis of tumor in vivo. Our finding uncovers the antitumorigenic effect of CHL in T-ALL progression through upregulating the expression of miR-9 and suppressing PD-L1 expression, which may provide a new potential strategy for T-ALL clinical treatment.

Entities:  

Keywords:  Chrysophanol; Growth and metastasis; PD-L1; T cell acute lymphoblastic leukemia; miR-9

Year:  2019        PMID: 31836919     DOI: 10.1007/s00210-019-01778-0

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  59 in total

Review 1.  Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs.

Authors:  James A McCubrey; Kvin Lertpiriyapong; Linda S Steelman; Steve L Abrams; Li V Yang; Ramiro M Murata; Pedro L Rosalen; Aurora Scalisi; Luca M Neri; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Piotr Laidler; Joanna Dulińska-Litewka; Dariusz Rakus; Agnieszka Gizak; Paolo Lombardi; Ferdinando Nicoletti; Saverio Candido; Massimo Libra; Giuseppe Montalto; Melchiorre Cervello
Journal:  Aging (Albany NY)       Date:  2017-06-12       Impact factor: 5.682

2.  Targeting of miR9/NOTCH1 interaction reduces metastatic behavior in triple-negative breast cancer.

Authors:  Samira Mohammadi-Yeganeh; Ardalan Mansouri; Mahdi Paryan
Journal:  Chem Biol Drug Des       Date:  2015-06-03       Impact factor: 2.817

3.  Chrysophanol Induces Apoptosis of Choriocarcinoma Through Regulation of ROS and the AKT and ERK1/2 Pathways.

Authors:  Whasun Lim; Changwon Yang; Fuller W Bazer; Gwonhwa Song
Journal:  J Cell Physiol       Date:  2016-06-02       Impact factor: 6.384

Review 4.  Continuing challenges and current issues in acute lymphoblastic leukemia.

Authors:  Ankit Kansagra; Saurabh Dahiya; Mark Litzow
Journal:  Leuk Lymphoma       Date:  2017-06-11

5.  Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.

Authors:  Eleni Anastasiadou; Dina Stroopinsky; Stella Alimperti; Alan L Jiao; Athalia R Pyzer; Claudia Cippitelli; Giuseppina Pepe; Martina Severa; Jacalyn Rosenblatt; Marilena P Etna; Simone Rieger; Bettina Kempkes; Eliana M Coccia; Shannan J Ho Sui; Christopher S Chen; Stefania Uccini; David Avigan; Alberto Faggioni; Pankaj Trivedi; Frank J Slack
Journal:  Leukemia       Date:  2018-06-26       Impact factor: 11.528

6.  miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2/MCL-1 Axis.

Authors:  Yanhui Liu; Pingchong Lei; Hong Qiao; Kai Sun; Xiling Lu; Fengchang Bao; Runhong Yu; Cheng Lian; Yao Li; Wei Chen; Fei Xue
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

Review 7.  Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application.

Authors:  Tom A Mulder; Björn E Wahlin; Anders Österborg; Marzia Palma
Journal:  Cancers (Basel)       Date:  2019-06-29       Impact factor: 6.639

8.  Expression of miR-9 and miR-200c, ZEB1, ZEB2 and E-cadherin in Non-Small Cell Lung Cancers in Iran.

Authors:  Bahareh Nourmohammadi; Elham Tafsiri; Amirabbas Rahimi; Zahra Nourmohammadi; Abolghasem Daneshvar Kakhaki; William Cho; Morteza Karimipoor
Journal:  Asian Pac J Cancer Prev       Date:  2019-06-01

9.  Upregulation of miR-124 by physcion 8-O-β-glucopyranoside inhibits proliferation and invasion of malignant melanoma cells via repressing RLIP76.

Authors:  Di Zhang; Yantao Han; Luo Xu
Journal:  Biomed Pharmacother       Date:  2016-09-19       Impact factor: 6.529

Review 10.  Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.

Authors:  Vera Kloten; Rita Lampignano; Thomas Krahn; Thomas Schlange
Journal:  Cells       Date:  2019-08-01       Impact factor: 6.600

View more
  4 in total

1.  Trametes robiniophila Murr Sensitizes Gastric Cancer Cells to 5-Fluorouracil by Modulating Tumor Microenvironment.

Authors:  Jing-Li Xu; Li Yuan; Can Hu; Chun-Yan Weng; Han-Dong Xu; Yun-Fu Shi; Ling Huang; Jie-Er Ying; Zhi-Yuan Xu; Jiang-Jiang Qin; Xiang-Dong Cheng
Journal:  Front Pharmacol       Date:  2022-05-17       Impact factor: 5.988

Review 2.  Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy.

Authors:  Xiangyu Deng; Zengwu Shao; Yanli Zhao
Journal:  Adv Sci (Weinh)       Date:  2021-01-05       Impact factor: 16.806

Review 3.  Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets.

Authors:  Zhangfeng Zhong; Chi Teng Vong; Feiyu Chen; Horyue Tan; Cheng Zhang; Ning Wang; Liao Cui; Yitao Wang; Yibin Feng
Journal:  Med Res Rev       Date:  2022-01-14       Impact factor: 12.388

4.  Chrysophanol Mitigates T Cell Activation by Regulating the Expression of CD40 Ligand in Activated T Cells.

Authors:  Hyun-Su Lee; Gil-Saeng Jeong
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.